Cit­ing tox­i­c­i­ty con­cerns, Boehringer In­gel­heim drops short-lived IPF pact — keep­ing $1B+ in its pock­et

Boehringer In­gel­heim has qui­et­ly killed a short-lived deal that it was pre­pared to spend $1.25 bil­lion on, re­turn­ing an ear­ly-stage drug to its Ko­re­an biotech …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER